{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:10:19Z","timestamp":1778544619913,"version":"3.51.4"},"reference-count":62,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:p>New therapies for haemophilia A have created momentum for enhancing protection against bleeding.<\/jats:p>\n                  <jats:p>The ultimate objective is to address remaining unmet needs and promote health equity.<\/jats:p>\n                  <jats:p>In this initiative, 14 haemophilia A experts from Europe (n\u2009=\u200913) and North America (n\u2009=\u20091) were involved to identify unmet needs in people with haemophilia A (PwHA) and measures to address these needs (e.g., normalization of factor VIII [FVIII] levels) to facilitate health equity. It combined online workshops, a modified Delphi process to develop consensus statements on remaining unmet medical needs (consensus was defined as \u226570% of panellists who gave a rating of 4 [agree] or 5 [strongly agree] using a 5-point Likert scale), and development of policy recommendations.<\/jats:p>\n                  <jats:p>Among the panellists who voted, consensus was reached on 25\/26 statements, including 13 with 100% agreement. The experts outlined a need to optimize prophylaxis in all eligible PwHA, aiming for high-sustained FVIII levels or normalized haemostasis. The panel also highlighted a need to prevent all bleeds (including microbleeds) that can occur despite prophylaxis, and to address chronic pain which is highly prevalent. Overall, 23 policy recommendations were finalized, which included the wider use of prophylaxis to reduce the burden of disease on PwHA and\/or provide normalized haemostasis, the expansion of multidisciplinary teams and the establishment of networks of expertise, and sharing of specialist knowledge.<\/jats:p>\n                  <jats:p>This initiative lays an ambitious foundation to rigorously evaluate unmet needs in PwHA and the determinants of health equity, offering a comprehensive set of recommendations to overcome barriers and achieve the possibility of normalization of haemostasis.<\/jats:p>","DOI":"10.1055\/a-2855-7618","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:44:53Z","timestamp":1778107493000},"source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Normalization of Haemostasis in People with Haemophilia A: Expert Consensus on Unmet Needs and a Framework for Advancing Towards Health Equity"],"prefix":"10.1055","volume":"10","author":[{"given":"Cedric","family":"Hermans","sequence":"additional","affiliation":[{"name":"Division of Haematology, Cliniques Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Auerswald","sequence":"additional","affiliation":[{"name":"Coagulation Centre, Bremen Central Clinic, GeNo Ltd., Parent-Child-Centre Prof. Hess, Bremen, Germany"},{"name":"Deutsche H\u00e4mophiliegesellschaft eV., Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Berrueco","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda Pedi\u00e1trica, Hospital Sant Joan de D\u00e9u de Barcelona, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Calvo","sequence":"additional","affiliation":[{"name":"European Association for Clinical Pharmacology and Therapeutics, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Christoforou","sequence":"additional","affiliation":[{"name":"Blood Unit and National Reference Center for Congenital Bleeding Disorders, \u201cLaiko\u201d General Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Anibal-Garc\u00eda","family":"Diego","sequence":"additional","affiliation":[{"name":"Fedhemo (Federaci\u00f3n Espa\u00f1ola de Hemofilia), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico Ferri","family":"Grazzi","sequence":"additional","affiliation":[{"name":"FedEmo (Federazione delle associazioni Emofilici), Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom"},{"name":"Department of Academic Haematology, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Pucek","sequence":"additional","affiliation":[{"name":"Czech Society of Hemophilia, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sedmina","sequence":"additional","affiliation":[{"name":"Slovak Hemophilia Society, Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Oxford, United Kingdom"},{"name":"Radcliffe Department of Medicine, Oxford University, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Skinner","sequence":"additional","affiliation":[{"name":"Institute for Policy Advancement Ltd, Washington, District of Columbia, United States"},{"name":"Department of Health Research Methods, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"S 06","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.12107","article-title":"Magnetic resonance imaging and ultrasound evaluation of \u201chealthy\u201d joints in young subjects with severe haemophilia A","volume":"19","author":"M N Di Minno","year":"2013","journal-title":"Haemophilia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JBM.S304597","article-title":"Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers","volume":"12","author":"R Gooding","year":"2021","journal-title":"J Blood Med"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtha.2023.01.035","article-title":"Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis","volume":"21","author":"F HP van Leeuwen","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"e052358","DOI":"10.1136\/bmjopen-2021-052358","article-title":"Twelve-month prevalence of haemarthrosis and joint disease using the Haemophilia Joint Health score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study","volume":"12","author":"R A Wilkins","year":"2022","journal-title":"BMJ Open"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/nu13030749","article-title":"Type 2 diabetes prevention focused on normalization of glycemia: a two-year pilot study","volume":"13","author":"A L McKenzie","year":"2021","journal-title":"Nutrients"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"M W Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207241285143","article-title":"Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions","volume":"15","author":"J Blatn\u00fd","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"S 03","key":"ref11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/hae.14964","article-title":"How much prophylaxis is enough in haemophilia?","volume":"30","author":"M Carcao","year":"2024","journal-title":"Haemophilia"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards achieving a haemophilia-free mind","volume":"29","author":"C Hermans","year":"2023","journal-title":"Haemophilia"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hae.15031","article-title":"Moving towards normalization of haemostasis and health equity: evolving treatment goals for haemophilia A","volume":"30","author":"P A Holme","year":"2024","journal-title":"Haemophilia"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"L Malec","year":"2023","journal-title":"Haemophilia"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2516.2007.01625.x","article-title":"European principles of haemophilia care","volume":"14","author":"B T Colvin","year":"2008","journal-title":"Haemophilia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207211007058","article-title":"Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study","volume":"12","author":"K Khair","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/hae.14934","article-title":"Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: a modified Delphi panel","volume":"30","author":"M Laffan","year":"2024","journal-title":"Haemophilia"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"e082204","DOI":"10.1136\/bmjopen-2023-082204","article-title":"Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries","volume":"14","author":"H De la Corte-Rodr\u00edguez","year":"2024","journal-title":"BMJ Open"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/08880018.2021.2004269","article-title":"Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review","volume":"39","author":"E Hassan","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/hae.14803","article-title":"Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: a systematic literature review","volume":"29","author":"P M Mannucci","year":"2023","journal-title":"Haemophilia"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2012.12727","article-title":"Association between physical activity and risk of bleeding in children with hemophilia","volume":"308","author":"C R Broderick","year":"2012","journal-title":"JAMA"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"P Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"I E den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"16","key":"ref26","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"J M Soucie","year":"2018","journal-title":"Blood Adv"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model","volume":"106","author":"A Tiede","year":"2021","journal-title":"Haematologica"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/a-1983-0594","article-title":"Association between sports participation, factor VIII levels and bleeding in hemophilia A","volume":"123","author":"L H Bukkems","year":"2023","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"B Madan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13023-025-03699-z","article-title":"The association of factor VIII activity levels with bleeding and quality of life in haemophilia a: findings from the European CHESS II study","volume":"20","author":"C Jones","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"A von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"P J Lenting","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1111\/hae.14407","article-title":"In response to WFH guidelines for the management of haemophilia, 3rd edition: is there a difference between extended-half-life FVIII products or not?","volume":"27","author":"E Berntorp","year":"2021","journal-title":"Haemophilia"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/hae.14691","article-title":"Area under the curve: comparing the value of factor VIII replacement therapies in haemophilia A","volume":"29","author":"S Persson","year":"2023","journal-title":"Haemophilia"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"103200","DOI":"10.1016\/j.rpth.2025.103200","article-title":"Normalization in hemophilia: conceptual foundations and clinical implications","volume":"9","author":"K Maneikis","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"M C Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hae.70113","article-title":"The WFH guidelines for the management of haemophilia: AAV gene therapy, 2025","volume":"32","author":"G F Pierce","year":"2026","journal-title":"Haemophilia"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/hae.14441","article-title":"Clinical assessment and point of care ultrasonography: how to diagnose haemophilic synovitis","volume":"28","author":"H De la Corte-Rodriguez","year":"2022","journal-title":"Haemophilia"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/hae.12375","article-title":"The burden of bleeding in haemophilia: is one bleed too many?","volume":"20","author":"A Gringeri","year":"2014","journal-title":"Haemophilia"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.04.012","article-title":"The hidden joint in children with haemophilia on prophylaxis","volume":"226","author":"C Daffunchio","year":"2023","journal-title":"Thromb Res"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11420-018-9604-x","article-title":"Point-of-care ultrasonography in orthopedic management of hemophilia: multiple uses of an effective tool","volume":"14","author":"H De la Corte-Rodriguez","year":"2018","journal-title":"HSS J"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.rpth.2024.102511","article-title":"Integrating musculoskeletal ultrasound as a shared decision-making tool in hemophilia care: observations from a 3-year study","volume":"8","author":"A Nagao","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13088","article-title":"Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective","volume":"23","author":"K Fischer","year":"2017","journal-title":"Haemophilia"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40814-018-0253-0","article-title":"The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia","volume":"4","author":"M W Skinner","year":"2018","journal-title":"Pilot Feasibility Stud"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"J O'Hara","year":"2021","journal-title":"Haemophilia"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/hae.15002","article-title":"The good, the bad and the ugly of pain in haemophilia: recent evidence on the epidemiology, molecular mechanisms and knowledge gaps preventing optimal treatment","volume":"30","author":"S Benemei","year":"2024","journal-title":"Haemophilia"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MBC.0000000000001199","article-title":"Chronic pain in haemophilia: assessment and analgesic treatment","volume":"34","author":"H De la Corte-Rodriguez","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"R Rayment","year":"2020","journal-title":"Br J Haematol"},{"issue":"09","key":"ref50","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"S M Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.15134","article-title":"Pain-related quality of life outcomes in people with haemophilia A receiving emicizumab: a post hoc analysis of the HAVEN 1, 3 and 4 and STASEY studies","volume":"31","author":"C Hermans","year":"2025","journal-title":"Haemophilia"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207221079482","article-title":"Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study","volume":"13","author":"J Pasi","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.blre.2021.100885","article-title":"Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement","volume":"51","author":"C Santoro","year":"2022","journal-title":"Blood Rev"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40122-021-00345-x","article-title":"Current and emerging approaches for pain management in hemophilic arthropathy","volume":"11","author":"R Gualtierotti","year":"2022","journal-title":"Pain Ther"},{"issue":"04","key":"ref57","first-page":"335","article-title":"Pain assessment and management in Italian haemophilia centres","volume":"19","author":"M ND Di Minno","year":"2021","journal-title":"Blood Transfus"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"C D Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474086.2024.2353761","article-title":"How clinicians and persons with hemophilia may approach shared decision-making","volume":"17","author":"C D Thornburg","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.12533","article-title":"Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey","volume":"21","author":"S Krishnan","year":"2015","journal-title":"Haemophilia"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/hae.15153","article-title":"Systematic literature review of outcomes associated with adherence to haemophilia drug therapy","volume":"31","author":"C Khanji","year":"2025","journal-title":"Haemophilia"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/hae.12499","article-title":"Compliance, concordance and adherence: what are we talking about?","volume":"20","author":"K Khair","year":"2014","journal-title":"Haemophilia"},{"key":"ref65","first-page":"s525","article-title":"The European standards of haemophilia centres","volume":"12","author":"P Giangrande","year":"2014","journal-title":"Blood Transfus"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hae.14766","article-title":"The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: analysis of the CHESS population studies","volume":"29","author":"P Chowdary","year":"2023","journal-title":"Haemophilia"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-022-02301-0","article-title":"Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study","volume":"17","author":"I Rodriguez-Santana","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-022-02300-1","article-title":"Differential humanistic and economic burden of mild, moderate and severe haemophilia in European adults: a regression analysis of the CHESS II study","volume":"17","author":"I Rodriguez-Santana","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1186\/s12913-024-11850-y","article-title":"Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies","volume":"24","author":"I Woollacott","year":"2024","journal-title":"BMC Health Serv Res"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2855-7618.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:17:24Z","timestamp":1778541444000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2855-7618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":62,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026]]}},"alternative-id":["a28557618"],"URL":"https:\/\/doi.org\/10.1055\/a-2855-7618","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,20]]},"published":{"date-parts":[[2026,4,20]]}}}